XACDURO is a new FDA-approved treatment used to fight against HABP/VABP infections caused by isolates of Acinetobacter baumannii-calcoaceticus complex, which can include those resistant to carbapenems ...

Researchers have found bacteria often associated with hospital infections in meat samples from markets in Peru. The Barcelona Institute for Global Health (ISGlobal) led the study, published in the ...

Credit: Innoviva. Xacduro is available as a kit containing a single dose vial of sulbactam 1g and 2 single-dose vials of durlobactam (0.5g in each vial). Xacduro ® (sulbactam for injection; ...

Credit: Getty Images. The investigational intravenous product is a combination of sulbactam, a β-lactam antibiotic, and durlobactam, a broad-spectrum β-lactamase inhibitor. The Food and Drug ...

Drug-resistant Acinetobacter baumannii is a growing global health threat and high priority pathogen needing new antibiotics, according to World Health Organization China NMPA approval based on ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved sulbactam-durlobactam for nosocomial pneumonia caused by drug-resistant Acinetobacter baumannii ...

Innoviva Inc's (NASDAQ: INVA) affiliate Entasis Therapeutics Inc received FDA approval for Xacduro (sulbactam and durlobactam for injection), co-packaged as a treatment for hospital-acquired pneumonia ...